Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Boosted by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC lifted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 8.3% in the third quarter, Holdings Channel.com reports. The firm owned 781,215 shares of the specialty pharmaceutical company’s stock after acquiring an additional 59,685 shares during the quarter. Jazz Pharmaceuticals comprises 1.3% of Thompson Siegel & Walmsley LLC’s portfolio, making the stock its 14th largest holding. Thompson Siegel & Walmsley LLC’s holdings in Jazz Pharmaceuticals were worth $87,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Versant Capital Management Inc lifted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $29,000. EverSource Wealth Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $33,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,110 shares of company stock worth $720,160. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 2.1 %

Shares of JAZZ stock opened at $119.24 on Thursday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.21 billion, a P/E ratio of 16.79, a P/E/G ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The firm has a 50-day moving average price of $112.64 and a 200 day moving average price of $110.45.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JAZZ. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, November 7th. Finally, TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $175.53.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.